ZTS logo

ZOETIS INC

ZTSNYSE
πŸ† #434 by market capEarnings Nov 2 Β· PreUS Equity
$70.53β–Ό $0.89 (βˆ’1.26%)
Live
πŸ””
Track ZTS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.3%
7dβ–Ό 3.1%
14dβ–Ό 3.9%
30dβ–Ό 8.8%
ytdβ–Ό 43.9%
1yβ–Ό 50.7%
🏦Market Cap
$29.57B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+2.3%
Slowing
πŸ“ŠGross Margin
70.9%
High
πŸ’΅FCF Margin
24.9%
Strong
βš–οΈP/S Ratio
3.1x
Fair
Otter Score
92
Very Good

Trading Snapshot

Day Range
$69.56 – $71.76
52-Week Range
$69.52 – $148.79
Volume
$2.90B
Avg Volume
$2.86B
Shares Outstanding
419.2M
Next Earnings
Nov 25, 2026

Fundamentals Snapshot

Annual Revenue
$9.47B
Last Q Revenue
$2.47B
P/E Ratio
11.7
P/S Ratio
3.1x
EPS (TTM)
$6.26
Dividend Yield
2.93%
Dilution (1yr)
βˆ’2.8%

Why Investors Own ZTS

  • βœ“High-growth profile β€” revenue up +54.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 60% gross margin and 18% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ZTS logo

ZOETIS INC

ZTS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9.5Bβ–² +2.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.5%β–² +2.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$3.6Bβ–² +6.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2.3Bβ–Ό βˆ’0.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
438.6Mβ–Ό βˆ’2.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$7.2Bβ–Ό βˆ’$2.4B YoY
StockOtter Β· stockotter.space

About ZOETIS INC

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
92/100

Analyst Ratings

β“˜
Consensus
Buy
24 analysts
Strong Buy4
Buy8
Hold12
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

Zacks Investment ResearchΒ·4d ago

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.

Business WireΒ·5d ago

Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive

Zacks Investment ResearchΒ·10d ago

Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note

Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.

Seeking AlphaΒ·11d ago

Zoetis: The Worst May Be Priced In

Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-mid single-digit growth potential. Q2 results disappointed, with flat revenues and declining U.S. sales, but internationa

MarketBeatΒ·11d ago

Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales

Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in d

Seeking AlphaΒ·12d ago

Zoetis: An Undervalued Compounder Hiding In Plain Sight

Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin